![]() |
Name |
3-Methylpentane
|
Molecular Formula | C6H14 | |
IUPAC Name* |
3-methylpentane
|
|
SMILES |
CCC(C)CC
|
|
InChI |
InChI=1S/C6H14/c1-4-6(3)5-2/h6H,4-5H2,1-3H3
|
|
InChIKey |
PFEOZHBOMNWTJB-UHFFFAOYSA-N
|
|
Synonyms |
3-METHYLPENTANE; 96-14-0; Pentane, 3-methyl-; 3-Methyl-pentane; Diethylmethylmethane; XD8O3ML76T; CHEBI:88373; NSC-66497; 3-Methylpentane, analytical standard; UNII-XD8O3ML76T; HSDB 5300; 3-methyl pentane; EINECS 202-481-4; NSC 66497; AI3-28852; 1,2-DIMETHYLBUTENE; 3-Methylpentane, >=99%; (C2H5)2CHCH3; CHEMBL357767; DTXSID8052647; NSC66497; ZINC1693925; MFCD00009342; AKOS015841880; DB-057623; FT-0616168; M0383; Q223107; J-002021
|
|
CAS | 96-14-0 | |
PubChem CID | 7282 | |
ChEMBL ID | CHEMBL357767 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 86.18 | ALogp: | 3.2 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 6 | QED Weighted: | 0.484 |
Caco-2 Permeability: | -4.201 | MDCK Permeability: | 0.00002320 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.016 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.058 |
30% Bioavailability (F30%): | 0.166 |
Blood-Brain-Barrier Penetration (BBB): | 0.99 | Plasma Protein Binding (PPB): | 83.78% |
Volume Distribution (VD): | 1.815 | Fu: | 13.94% |
CYP1A2-inhibitor: | 0.922 | CYP1A2-substrate: | 0.857 |
CYP2C19-inhibitor: | 0.303 | CYP2C19-substrate: | 0.844 |
CYP2C9-inhibitor: | 0.387 | CYP2C9-substrate: | 0.436 |
CYP2D6-inhibitor: | 0.036 | CYP2D6-substrate: | 0.136 |
CYP3A4-inhibitor: | 0.033 | CYP3A4-substrate: | 0.227 |
Clearance (CL): | 9.511 | Half-life (T1/2): | 0.528 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.024 |
Drug-inuced Liver Injury (DILI): | 0.045 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.112 | Maximum Recommended Daily Dose: | 0.024 |
Skin Sensitization: | 0.176 | Carcinogencity: | 0.12 |
Eye Corrosion: | 0.992 | Eye Irritation: | 0.994 |
Respiratory Toxicity: | 0.398 |